Medical Treatments for Erectile Dysfunction
|
The 1980s saw a raising break away from psychological handling of sexual disorders to an emphasis on surgical and medical solutions for bettering sexual health. At the same time, there was a advanced shift within the medical community and public at large, towards seeing the etiology of sexual disorders as organic, rather than the psychogenic understanding emphasised by sex therapists. Exercise of improved sophisticated diagnostic processes, such as duplex sonography and cavernosograms (although not necessarily bettering treatment) contributed credibility and imprimatur to the importance of organic pathogenesis. This was particularly true in the area of erectile dysfunction, where urologists evidenced control, with the prosperous marketing and practice of different intracavernosal and intraurethral systems. Although highly bragged by urologists, the treatment efficacy of these products was offset by their intrusiveness into the patients bodies and reduction in spontaneity, their models of use essential.
Initially, there were few oral treatments for erectile dysfunction, being utilized by urologists, such as yohimbine based products, trazodone, and bupropion. They had only modest proerectile capability. Pharmaceutical companies were inspired to follow up on oral treatments with the promise of less intrusiveness and even larger benefits. The first visible evidence of accomplishing that predict was the sildenafil launch. Accompanying to Pfizers success, multiple companies simultaneously pursued clinical tests of easy-to-use handling for male sexual disorders. Among others, these included additional PDE-5 type compounds and other oral treatments, such as ixense, and topically implemented compounds. Additionally, PT-141 (Palatin Technology, Cranbury, NJ, USA) is a nasally administered peptide that is under development, which is assumed to work through a central nervous system mechanism.
Currently, there are three highly effective PDE-5, FDA-approved treatments for erectile dysfunction: sildenafil, vardenafil, and tadalafil. Reviews of long-term extension analyses and released accounts of usage in clinical practice show that sildenafil's strength was maintained with long-term treatment. Importantly Combination Therapy for Sexual Dysfunction better erectile function was proved for sildenafil compared with placebo for all efficacy parameters studied, regardless of patient age, race, body mass index, erectile dysfunction etiology, erectile dysfunction severity, erectile dysfunction duration, or the presence of various co morbidities. Long-term effectivity was assessed in three open-label reference studies. Vardenafil (launched in 2003) is a potent, selective PDE-5 inhibitor, which improved erectile function in a broad population of men with erectile dysfunction and in characteristically challenging-to-treat groups such as diabetic and post prostatectomy patients. Tadalafil also launched in 2003, when taken, as needed before sexual activity and without restrictions on food or alcohol intake, significantly better erectile function. It permitted a essential proportion of patients to reach a normal IIEF erectile function domain score, exposed a broad window of therapeutic responsiveness and was well permitted in a representative population of patients with broadspectrum erectile dysfunction. |
|
Author Resource:-
David Crawford is the CEO and owner of a Male Enhancement Products company known as Male Enhancement Group which is dedicated to researching and comparing male enhancement products in order to determine which male enhancement product is safer and more effective than other products on the market. Copyright 2010 David Crawford of http://www.maleenhancementgroup.com This article may be freely distributed if this resource box stays attached.
|
By :
David Jamesonsess
Submitted
2010-05-20 22:20:45 |
Article From Article Mayhem
Ezine ready view |
|
|
|
Related Articles
|
|
|